Navigation Links
Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
Date:12/1/2008

MORRISTOWN, N.J., Dec. 1 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 150mg. Distribution of the product has commenced.

Bupropion Hydrochloride extended-release tablets (XL), available in 150 & 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual U.S. sales of brand and generic Wellbutrin XL(R) were US$1,481 million for the 12 months ending September 2008 according to IMS Health data.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the United States said:

"Bupropion XL 150mg, together with 300mg which was launched in August this year, offers significant value to our customers and patients. This approval also underscores Actavis' emphasis and capability in bringing complex controlled-release products to the marketplace."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
2. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
3. Actavis Extends Portfolio With Four New Products in the U.S.
4. Actavis Confirms its Patent Challenge of Kings Avinza(R)
5. Actavis Launches Amlodipine Tablets in the U.S.
6. Actavis Launches Carvedilol Tablets in the U.S.
7. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
8. EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
9. Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award
10. ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications
11. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Over $60 Billion is spent annually on products ... toys, leading product review site for Toys, Tots, Pets & More (TTPM) announced the ... Spring Showcase at the Metropolitan Pavilion in New York City. , Chosen from a ...
(Date:5/2/2016)... Las Vegas, NV (PRWEB) , ... May 02, ... ... with Specialty Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award ... be determined based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy ...
(Date:5/2/2016)... ... May 02, 2016 , ... According to an American Psychological Association ... are sexually abused before the age of 18. Of those who survive, many still ... and others. , In her new book, Lyah! Lyah! Pants on Fyah!, she ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... Analytics EVP and GM Jim Callandrillo and Duane Reed, VP of business ... Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting from May ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- which specializes in ... the outcome of their partnership with Yoloha Yoga- producers of high quality cork yoga ... SUP yoga has seen a dramatic rise in popularity throughout the last few years. ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
(Date:4/28/2016)... Net Sales of $1.90 billion represent an increase of 67.8% ... an increase of 1.2% on an adjusted pro forma, constant ... were $0.52 reported, a decrease of 47.5% from the prior ... the prior year period , The Company increases constant ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ...
Breaking Medicine Technology: